| In humans, sudden withdrawal of SRI/SSRI/TCA drugs is associated with dysphoria, agitation, increased anxiety, relapse of psychiatric symptoms and, in some cases discontinuation syndrome<ref>Haddad, P.M., Anderson, I.A. (2007) Recognising and managing antidepressant discontinuation symptoms. Advances in Psychiatric Treatment. 13, 447-457</ref>. It is recommended that, unless otherwise indicated by drug monographs, withdrawal should be gradual. Typically a period of 1 week per month of treatment is allowed for withdrawal. This is divided into three periods of equal length with three dose decreases to 75% of original dose, followed by 50% of original dose and finally 25% of original dose. | | In humans, sudden withdrawal of SRI/SSRI/TCA drugs is associated with dysphoria, agitation, increased anxiety, relapse of psychiatric symptoms and, in some cases discontinuation syndrome<ref>Haddad, P.M., Anderson, I.A. (2007) Recognising and managing antidepressant discontinuation symptoms. Advances in Psychiatric Treatment. 13, 447-457</ref>. It is recommended that, unless otherwise indicated by drug monographs, withdrawal should be gradual. Typically a period of 1 week per month of treatment is allowed for withdrawal. This is divided into three periods of equal length with three dose decreases to 75% of original dose, followed by 50% of original dose and finally 25% of original dose. |